NL990012I2 - Geneesmiddelen die salmeterol en fluticason bevatten. - Google Patents

Geneesmiddelen die salmeterol en fluticason bevatten.

Info

Publication number
NL990012I2
NL990012I2 NL990012C NL990012C NL990012I2 NL 990012 I2 NL990012 I2 NL 990012I2 NL 990012 C NL990012 C NL 990012C NL 990012 C NL990012 C NL 990012C NL 990012 I2 NL990012 I2 NL 990012I2
Authority
NL
Netherlands
Prior art keywords
fluticasone
medicines containing
salmeterol
containing salmeterol
inhalation
Prior art date
Application number
NL990012C
Other languages
English (en)
Dutch (nl)
Other versions
NL990012I1 (nl
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL990012(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NL990012I1 publication Critical patent/NL990012I1/nl
Publication of NL990012I2 publication Critical patent/NL990012I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NL990012C 1989-09-08 1999-04-14 Geneesmiddelen die salmeterol en fluticason bevatten. NL990012I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (2)

Publication Number Publication Date
NL990012I1 NL990012I1 (nl) 1999-07-01
NL990012I2 true NL990012I2 (nl) 1999-09-01

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
NL990012C NL990012I2 (nl) 1989-09-08 1999-04-14 Geneesmiddelen die salmeterol en fluticason bevatten.

Country Status (20)

Country Link
EP (1) EP0416951B1 (cg-RX-API-DMAC10.html)
JP (1) JP3042867B2 (cg-RX-API-DMAC10.html)
AT (1) ATE99941T1 (cg-RX-API-DMAC10.html)
BE (1) BE1003053A3 (cg-RX-API-DMAC10.html)
CA (1) CA2024916C (cg-RX-API-DMAC10.html)
CH (1) CH680983C9 (cg-RX-API-DMAC10.html)
DE (2) DE69005951T2 (cg-RX-API-DMAC10.html)
DK (1) DK0416951T3 (cg-RX-API-DMAC10.html)
ES (1) ES2062392T3 (cg-RX-API-DMAC10.html)
FR (1) FR2651677B1 (cg-RX-API-DMAC10.html)
HK (1) HK18695A (cg-RX-API-DMAC10.html)
HU (1) HU211272A9 (cg-RX-API-DMAC10.html)
IE (1) IE65535B1 (cg-RX-API-DMAC10.html)
IL (1) IL95590A (cg-RX-API-DMAC10.html)
IT (1) IT1241996B (cg-RX-API-DMAC10.html)
LU (1) LU90392I2 (cg-RX-API-DMAC10.html)
NL (1) NL990012I2 (cg-RX-API-DMAC10.html)
NZ (1) NZ235221A (cg-RX-API-DMAC10.html)
PH (1) PH27594A (cg-RX-API-DMAC10.html)
SG (1) SG166294G (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
IT1317904B1 (it) 1999-09-11 2003-07-15 Glaxo Group Ltd Formulazione farmaceutica di propionato di fluticasone.
DE60019167T2 (de) * 1999-12-24 2006-05-11 Glaxo Group Ltd., Greenford Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
ATE416184T1 (de) 2000-08-05 2008-12-15 Glaxo Group Ltd 17.beta.-carbothioat 17.alpha.- arylkarbonyloxyloxy androstanderivate als anti- phlogistische medikamente
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2288543T3 (es) 2001-03-08 2008-01-16 Glaxo Group Limited Agonistas de beta-adrenorreceptores.
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
PL393155A1 (pl) 2001-09-14 2011-03-28 Glaxo Group Limited Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
AU2003205855A1 (en) † 2002-02-04 2003-09-02 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
CA2477714C (en) * 2002-03-04 2011-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
WO2005013963A1 (en) 2003-08-06 2005-02-17 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
WO2005087192A2 (en) * 2004-03-12 2005-09-22 Cipla Limited Salmeterol inhalation formulations
AU2005263486B2 (en) 2004-07-16 2011-05-12 Astrazeneca Ab Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
AU2007338305B2 (en) 2006-12-22 2013-05-09 Astrazeneca Ab Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
PL2435024T3 (pl) 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
MX2015015132A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
LU90392I2 (fr) 1999-06-28
IL95590A (en) 1996-06-18
CH680983A5 (cg-RX-API-DMAC10.html) 1992-12-31
HU211272A9 (en) 1995-11-28
JP3042867B2 (ja) 2000-05-22
EP0416951B1 (en) 1994-01-12
CH680983C1 (cg-RX-API-DMAC10.html) 2008-06-25
CA2024916C (en) 2002-07-09
SG166294G (en) 1995-06-16
HK18695A (en) 1995-02-17
IL95590A0 (en) 1991-09-16
NL990012I1 (nl) 1999-07-01
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
BE1003053A3 (fr) 1991-11-05
DE69005951D1 (de) 1994-02-24
DE19975040I2 (de) 2006-07-13
NZ235221A (en) 1992-11-25
FR2651677B1 (fr) 1993-08-06
FR2651677A1 (fr) 1991-03-15
CH680983C9 (cg-RX-API-DMAC10.html) 2008-08-15
PH27594A (en) 1993-08-31
JPH03167120A (ja) 1991-07-19
IE903256A1 (en) 1991-03-13
DK0416951T3 (da) 1994-02-14
IT9048260A0 (it) 1990-09-07
DE69005951T2 (de) 1994-05-26
IE65535B1 (en) 1995-11-01
IT1241996B (it) 1994-02-02
ATE99941T1 (de) 1994-01-15
EP0416951A1 (en) 1991-03-13
CA2024916A1 (en) 1991-03-09

Similar Documents

Publication Publication Date Title
NL990012I1 (nl) Geneesmiddelen die salmeterol en fluticason bevatten.
DE69002718D1 (de) Medikamente.
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
CA2123909A1 (en) New combination of formoterol and budesonide
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
ZA888461B (en) Azelastine-containing medicaments for application in the nose and/or at the eye
DE68929388D1 (de) Aus Harn isolierte antikoagulierende Verbindung
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69004532D1 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
DE69918961D1 (de) Verbesserte inhalationspräparate
MY111155A (en) Medicaments
JPS6438027A (en) Remedy for cancer
RU93003454A (ru) Лекарственный препарат